Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Citius Pharmaceuticals Inc (CTXR)

Citius Pharmaceuticals Inc (CTXR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ PR Newswire - Fri Feb 13, 7:00AM CST

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar PR Newswire - Wed Feb 11, 7:00AM CST

Third international distribution agreement further advances global access strategy with major markets in Europe

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update PR Newswire - Tue Dec 23, 2025

Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025

CTXR : 0.7090 (+2.60%)
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update PR Newswire - Tue Dec 23, 2025

Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules PR Newswire - Tue Dec 9, 2025

Proceeds strengthen cash position and support commercial launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL)

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim PR Newswire - Thu Dec 4, 2025

Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) PR Newswire - Mon Dec 1, 2025

LYMPHIR now available nationwide

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration PR Newswire - Fri Nov 21, 2025

Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch

CTXR : 0.7090 (+2.60%)
CTOR : 1.1600 (-4.13%)
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules PR Newswire - Tue Oct 21, 2025

CRANFORD, N.J. , Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization...

CTXR : 0.7090 (+2.60%)
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules PR Newswire - Tue Oct 21, 2025

CRANFORD, N.J. , Oct. 21, 2025 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization...

CTXR : 0.7090 (+2.60%)

Barchart Exclusives

How Did Markets Open the Week? Barchart - 15 minutes ago
A lot happened that was expected to (US Supreme Court decision and reaction from the White House), and didn't happen that was expected to (military action) since last Friday's close. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot